Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.46Last Year’s EPS
-0.7Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -5.33%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The call highlighted significant clinical progress, strategic partnerships, and operational efficiency, with substantial advancements in solid tumor and ARDS treatments. Although there was a delay in government funding, the overall sentiment remains positive due to the strong performance and strategic advancements.Company Guidance
During the first quarter of 2025, MiNK Therapeutics reported significant progress in several key areas, focusing primarily on their scalable iNKT cell therapies for solid tumors and immune-related diseases. The company achieved a 47% year-on-year reduction in operating cash burn, maintaining financial efficiency to support core program investments. In their clinical trials, MiNK made strides with their second-line gastric cancer program and continued development in ARDS and GvHD. Their strategic initiatives included advancing confidential proposals that could enhance their operational runway and accelerate impact. These proposals focus on oncology, immunology, and their next-generation pipeline, aiming to leverage distinct partner capabilities to foster growth. MiNK highlighted compelling clinical data, including a complete response in a metastatic testicular cancer patient and promising survival rates in ARDS cases. Financially, the company ended the quarter with $3.2 million in cash, reducing the net loss to $2.8 million, or $0.70 per share, compared to $3.8 million, or $1.10 per share, in the previous year.Clinical Progress in Solid Tumors
Presented new data in solid tumors, specifically in second-line gastric cancer, showing immune activation and very early clinical activity in patients refractory to checkpoint modulating antibodies.
Capital Efficiency
Continued reduction in operating cash burn by about 47% year-on-year, preserving the ability to invest in core programs.
Strategic Partnerships
Advancing three distinct proposals aligned with key therapeutic areas in oncology, cancer, and immunology, which could extend runway and accelerate impact.
Testicular Cancer Complete Response
Reported a complete response in a patient with metastatic testicular cancer treated with agenT-797, achieving durable remission without lymphodepletion or HLA matching.
Advancements in ARDS Treatment
Data showed improved survival and meaningful inflammatory control in critically ill ventilated patients with ARDS, with observed survival rates exceeding 70%.
Operational Efficiency
Reduced operating burn and retained top scientific leaders, allowing for more efficient and less capital-intensive operations.
INKT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INKT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $7.50 | $7.18 | -4.27% |
Mar 18, 2025 | $8.52 | $8.24 | -3.29% |
Nov 14, 2024 | $7.94 | $7.50 | -5.54% |
Aug 13, 2024 | $8.35 | $8.49 | +1.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MiNK Therapeutics (INKT) report earnings?
MiNK Therapeutics (INKT) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is MiNK Therapeutics (INKT) earnings time?
MiNK Therapeutics (INKT) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INKT EPS forecast?
INKT EPS forecast for the fiscal quarter 2025 (Q2) is -0.46.